Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that intradermal injection of cholesterol-modified siRNA targeting FGF5 or FGF18, or topical application of FGF18-targeted siRNA, effectively influenced hair follicle cycles in mice, suggesting potential benefits for alopecia management.

This study found that DKK1-targeting siRNA, which may activate the Wnt/β-catenin signaling pathway, showed hair growth results in mice similar to those treated with the FDA-approved minoxidil, suggesting potential as an androgenetic alopecia therapy.

This study found that a chemically modified small-interfering RNA candidate, AR-27 E-Chol, effectively stimulated hair regrowth and reduced androgen receptor gene expression in a mouse model of androgenetic alopecia, indicating its potential as a novel therapeutic approach.

This study evaluated a chemically modified siRNA, AR-27 E-Chol, which effectively promoted hair regrowth and reduced androgen receptor gene expression in a DHT-induced mouse model of androgenetic alopecia, suggesting its potential as a novel therapeutic candidate.

This study found that a cholesterol-conjugated, cell-penetrating asiRNA targeting the androgen receptor effectively reduced hair loss and promoted hair growth in mouse models of androgenetic alopecia, suggesting potential as a novel treatment.